These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1584 related articles for article (PubMed ID: 33246024)

  • 21. Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries.
    Htoo PT; Stürmer T; Jonsson-Funk M; Pate V; Simpson RJ; Lund JL
    Epidemiology; 2019 Nov; 30(6):867-875. PubMed ID: 31348009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study.
    Voskamp PWM; Dekker FW; van Diepen M; Hoogeveen EK;
    J Am Soc Hypertens; 2017 Oct; 11(10):635-643. PubMed ID: 28802945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis.
    Lin YC; Lin JW; Wu MS; Chen KC; Peng CC; Kang YN
    PLoS One; 2017; 12(12):e0188975. PubMed ID: 29240784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
    Ku E; McCulloch CE; Vittinghoff E; Lin F; Johansen KL
    J Am Heart Assoc; 2018 Oct; 7(19):e009992. PubMed ID: 30371331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
    Shih CJ; Chen HT; Chao PW; Kuo SC; Li SY; Yang CY; Tarng DC; Ou SM; Chen YT
    J Hypertens; 2016 Mar; 34(3):567-74; discussion 575. PubMed ID: 26703918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study.
    Zhan M; Doerfler RM; Xie D; Chen J; Chen HY; Diamantidis CJ; Rahman M; Ricardo AC; Sondheimer J; Strauss L; Wagner LA; Weir MR; Fink JC;
    Am J Kidney Dis; 2020 Aug; 76(2):184-193. PubMed ID: 32317121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.
    Qiao Y; Shin JI; Chen TK; Inker LA; Coresh J; Alexander GC; Jackson JW; Chang AR; Grams ME
    JAMA Intern Med; 2020 May; 180(5):718-726. PubMed ID: 32150237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers.
    Choksi TT; Zhang H; Chen T; Malhotra N
    Am J Nephrol; 2021; 52(3):250-260. PubMed ID: 33827074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.
    Hsiao FC; Tung YC; Chou SH; Wu LS; Lin CP; Wang CL; Lin YS; Chang CJ; Chu PH
    Medicine (Baltimore); 2015 Dec; 94(51):e2355. PubMed ID: 26705234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
    Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4-5: Eight-Year Follow-up.
    de Rooij ENM; de Fijter JW; Le Cessie S; Hoorn EJ; Jager KJ; Chesnaye NC; Evans M; Windahl K; Caskey FJ; Torino C; Szymczak M; Drechsler C; Wanner C; Dekker FW; Hoogeveen EK;
    Am J Kidney Dis; 2023 Sep; 82(3):257-266.e1. PubMed ID: 37182596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2020; 40(1):38-45. PubMed ID: 31196659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care.
    Haroon S; Subramanian A; Cooper J; Anand A; Gokhale K; Byne N; Dhalla S; Acosta-Mena D; Taverner T; Okoth K; Wang J; Chandan JS; Sainsbury C; Zemedikun DT; Thomas GN; Parekh D; Marshall T; Sapey E; Adderley NJ; Nirantharakumar K
    BMC Infect Dis; 2021 Mar; 21(1):262. PubMed ID: 33722197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.
    Bhandari S; Ives N; Brettell EA; Valente M; Cockwell P; Topham PS; Cleland JG; Khwaja A; El Nahas M
    Nephrol Dial Transplant; 2016 Feb; 31(2):255-61. PubMed ID: 26429974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.
    Semenzato L; Botton J; Drouin J; Baricault B; Vabre C; Cuenot F; Penso L; Herlemont P; Sbidian E; Weill A; Dray-Spira R; Zureik M
    Hypertension; 2021 Mar; 77(3):833-842. PubMed ID: 33423528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac Effects of Renin-Angiotensin System Inhibitors in Nonproteinuric CKD.
    Shulman RS; Yang W; Cohen DL; Reese PP; Cohen JB;
    Hypertension; 2024 Oct; 81(10):2082-2090. PubMed ID: 39087321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone.
    Kim-Mitsuyama S; Ogawa H; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K
    Kidney Int; 2013 Jan; 83(1):167-76. PubMed ID: 23051740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 80.